Immunohistochemical study of nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 in invasive breast carcinoma of no special type

Symonowicz,Krzysztof; Duś-Szachniewicz,Kamila; Woźniak,Marta; Murawski,Marek; Kołodziej,Paweł; Osiecka,Beata; Jurczyszyn,Kamil; Ziółkowski,Piotr

doi:10.3892/etm.2014.1847

Immunohistochemical study of nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 in invasive breast carcinoma of no special type

Authors:
- Krzysztof Symonowicz
- Kamila Duś-Szachniewicz
- Marta Woźniak
- Marek Murawski
- Paweł Kołodziej
- Beata Osiecka
- Kamil Jurczyszyn
- Piotr Ziółkowski
View Affiliations

Affiliations: Department of Pathology, Wrocław Medical University, Wrocław, Lower Silesia 50‑368, Poland, Department of Gynecology and Obstetrics, Wrocław Medical University, Wrocław, Lower Silesia 50‑368, Poland, Division of Pathology, Sokołowski Regional Hospital, Wałbrzych, Lower Silesia 58-309, Poland
Published online on: July 16, 2014 https://doi.org/10.3892/etm.2014.1847
Pages: 1039-1046

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the immunohistochemical expression of nuclear ubiquitous casein and cyclin‑dependent kinases substrate 1 (NUCKS1) in invasive breast carcinoma of no special type, in association with clinicopathological characteristics, including the tumor grade, frequency of lymph node involvement and distant metastasis. In addition, associations between NUCKS1 and other tumor subtype markers, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki‑67 and cytokeratin 5/6 (CK 5/6), were investigated. NUCKS1 expression was shown to be associated with the formation of distant metastases and lymph node involvement. Furthermore, an association between the presence of NUCKS1 and histological grading was observed. The results confirmed that the expression of NUCKS1 in low grade invasive breast carcinoma of no special type was significantly less common compared with cases of high grade carcinoma. With regard to the additional tumor subtype markers, NUCKS1 expression was demonstrated to be significantly associated with Ki‑67 and CK 5/6; however, no association was identified with ER, PR and HER2. Therefore, NUCKS1 may be a novel prognostic marker in the histopathological evaluation of invasive breast carcinoma of no special type.

View Figures

View References

1	Grundt K, Haga IV, Aleporou-Marinou V, Drosos Y, Wanvik B and Østvold AC: Characterization of the NUCKS gene on human chromosome 1q32.1 and the presence of a homologous gene in different species. Biochem Biophys Res Comm. 323:796–801. 2004. View Article : Google Scholar : PubMed/NCBI
2	Ostvold AC, Norum JH, Mathiesen S, Wanvik B, Sefland I and Grundt K: Molecular cloning of a mammalian nuclear phosphoprotein NUCKS, which serves as a substrate for Cdk1 in vivo. Eur J Biochem. 268:2430–2440. 2001. View Article : Google Scholar
3	Wiśniewski JR and Schwanbeck R: High mobility group I/Y: multifunctional chromosomal proteins causally involved in tumor progression and malignant transformation (review). Int J Mol Med. 6:409–419. 2000.
4	Fusco A and Fedele M: Roles of HMGA proteins in cancer. Nat Rev Cancer. 7:899–910. 2007. View Article : Google Scholar
5	Belge G, Meyer A, Klemke M, Burchardt K, Stern C, Wosniok W, Loeschke S and Bullerdiek J: Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer. 47:56–63. 2008. View Article : Google Scholar : PubMed/NCBI
6	Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O’Dwyer PJ, Fero MJ, Kristensen GB, Borresen-Dale AL, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO and Sikic BI: Gene expression patterns in ovarian carcinomas. Mol Biol Cell. 14:4376–4386. 2003. View Article : Google Scholar : PubMed/NCBI
7	Kikuchi A, Ishikawa T, Mogushi K, Ishiguro M, Iida S, Mizushima H, Uetake H, Tanaka H and Sugihara K: Identification of NUCKS1 as a colorectal cancer prognostic marker through integrated expression and copy number analysis. Int J Cancer. 132:2295–2302. 2013. View Article : Google Scholar : PubMed/NCBI
8	Smalley M and Ashworth A: Stem cells and breast cancer: a field in transit. Nat Cancer. 3:832–844. 2003. View Article : Google Scholar : PubMed/NCBI
9	Weigelt B, Geyer FC, Horlings HM, Kreike B, Halfwerk H and Reis-Filho JS: Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol. 22:1401–1414. 2009. View Article : Google Scholar : PubMed/NCBI
10	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ; Panel members. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
11	Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS and Millikan RC: Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
12	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO and Botstein D: Molecular portraits of human breast tumors. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
13	Ziółkowski P, Gamian E, Osiecka B, Zougman A and Wiśniewski JR: Immunohistochemical and proteomic evaluation of nuclear ubiquitous casein and cyclin-dependent kinases substrate in invasive ductal carcinoma of the breast. J Biomed Biotechnol. 2009:9196452009.PubMed/NCBI
14	Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R and Carvalho FM: Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas. Histopathology. 55:346–352. 2009. View Article : Google Scholar
15	Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ and Nielsen TO: Ki-67 index, HER2 status and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar
16	Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar
17	Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 111:155–168. 1998.PubMed/NCBI
18	McClave JT, Benson PG and Sincich T: A First Course in Business Statistics. 17th edition. Prentice-Hall, Inc; New York, NY: 1998
19	Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH, Tsai ST, Jeng YM, Shew JY, Kung JT, Chen CH, Lee EY, Chang KJ and Lee WH: Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One. 4:e83772009. View Article : Google Scholar : PubMed/NCBI
20	Skaland I, Janssen EA, Gudlaugsson E, Hui Ru Guo L and Baak JP: The prognostic value of the proliferation marker phosphohistone H3 (PPH3) in luminal, basal-like and triple negative phenotype invasive lymph node-negative breast cancer. Cell Oncol. 31:261–271. 2009.
21	Grundt K, Skjeldal L, Anthonsen HW, Skauge T, Huitfeldt HS and Østvold AC: A putative DNA-binding domain in the NUCKS protein. Arch Biochem Biophys. 407:168–175. 2002. View Article : Google Scholar : PubMed/NCBI
22	Wiśniewski JR, Zougman A, Krüger S, Ziółkowski P, Pudełko M, Bebenek M and Mann M: Constitutive and dynamic phosphorylation and acetylation sites on NUCKS, a hypermodified nuclear protein, studied by quantitative proteomics. Proteins. 73:710–718. 2008.PubMed/NCBI
23	Bernardi MA, Logullo AF, Pasini FS, Nonogaki S, Blumke C, Soares FA and Brentani MM: Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer. Oncol Rep. 27:28–38. 2012.PubMed/NCBI
24	Yanagawa M, Ikemot K, Kawauchi S, Furuya T, Yamamoto S, Oka M, Oga A, Nagashima Y and Sasaki K: Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. BMC Res Notes. 5:3762012. View Article : Google Scholar : PubMed/NCBI
25	Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM and Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 14:1368–1376. 2008. View Article : Google Scholar : PubMed/NCBI
26	Chu PG and Weiss LM: Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol. 15:6–10. 2012.
27	Khilko N, Wang J, Wei B, Hicks DG and Tang P: Invasive lobular carcinomas do not express basal cytokeratin markers CK 5/6, CK 14 and CK 17. Breast Cancer (Auckl). 21:49–55. 2010.PubMed/NCBI
28	Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI and Ellis IO: Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 203:661–671. 2004.PubMed/NCBI